Welcome Back to the MenWithFibro Forums
It does not matter the name, We all have the same symptoms.

Main Menu

ShoutBox! For quick short shout outs to other members. For introductions, questions or comments please post in the proper sections of the forum.

2023 Nov 18 19:10:11
ronr: Sorry folks but we have to move again.  Finances is the major reason and but the new hosting service is kicking back tons of errors and things just aren't work well!  I cleaned out the shoutbox just so that the changes messages will stand out better!

2023 Nov 18 19:06:32
ronr: Facebook does not allow nearly the amount of privacy and they search for people and groups thatdon't follow their guidelines.

2023 Nov 13 19:25:44
ronr: This link is an invitation for those that would like to follow us!

2023 Nov 13 19:25:04
ronr: Discord is new to most of us but there is a GREAT DEAL of privacy there.  You need to be invited to even see our page.  Download of the app is easy and there are plenty of directions

FDA - Recall of a Single Lot of Hydromorphone

Started by ronr, December 24, 2008, 09:45:19 AM

Previous topic - Next topic

0 Members and 21 Guests are viewing this topic.


Recall -- Firm Press Release
FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

ETHEX Corporation Initiated Nationwide Voluntary Recall of a Single Lot of Hydromorphone HCl 2 mg Tablets Due to Potential for Oversized Tablet
Ann McBride

FOR IMMEDIATE RELEASE -- St. Louis, MO – December 23, 2008 – ETHEX Corporation announced today that it has voluntarily recalled to the consumer level, a single production lot of Hydromorphone HCl 2 mg tablets (Lot #90219, Exp: 03/2010; NDC #58177-0620-04), as a precaution, due to the possibility it may contain oversized tablets. Hydromorphone is a drug used for pain management and is packaged under the ETHEX label in 100-count bottles.

If someone were to take a higher than expected dose of Hydromorphone, the risk of adverse effects known to be associated with the drug may be increased, including respiratory depression (difficulty or lack of breathing), low blood pressure, and sedation.

There are other companies in the United States producing and marketing versions of Hydromorphone HCl tablets and consumers and their caregivers are encouraged to check their prescriptions to determine the source of their tablets. Hydromorphone HCl 2 mg tablets marketed by ETHEX are a blue, round tablet with a script "E" on one side and a "2" on the other side.

ETHEX Corporation has initiated recall notifications to wholesalers and retailers nationwide who have received any inventory of the recalled lot of this product with instructions for returning the recalled product and, if they have not already done so, they are urged to contact ETHEX as provided below regarding procedures for returning the recalled product. If consumers have any questions about the recall, they should call the telephone number below or their physician, pharmacist, or other health care provider.

Any customer inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-748-1472 or fax to ETHEX Customer Service at 314-646-3751, or e-mail to Representatives are available Monday through Friday, 8 am to 5 pm CST. Consumers who experience any adverse reactions to this drug should contact their physician and/or healthcare provider immediately. Any adverse reactions experienced with the use of this product, and/or quality problems may also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at

The Hydromorphone HCl recall announcement is posted on and It includes step-by-step details on how to return affected product to KV Pharmaceutical. The Company web site also includes a list of the drugs affected by the suspension.

The parent company of ETHEX Corporation, KV Pharmaceutical has advised the U.S. Food and Drug Administration that, effective midnight Dec. 19, 2008, the company voluntarily suspended shipments of all FDA-approved drug products in tablet form. This action is being taken as a precautionary measure, to allow KV to expeditiously address manufacturing issues that have come to management's attention, to review and enhance comprehensively the company's quality systems, and to implement efficiency improvements in its production facilities. KV is keeping the FDA informed about the Company's plans.

This recall and suspension are being conducted with the knowledge of the FDA. At this time, the company is unable to determine when distribution of tablet form products will resume, or estimate what the financial impact of the recall and suspension will be.

Times are tough when "Happy Hour" is your nap.
My mind not only wanders, sometimes it leaves completely!

SMF spam blocked by CleanTalk